BNTC · Benitec Biopharma Inc.
$13.48
+0.47 (+3.61%)
At close · Aug 21
Market Cap
$463.10M
Shares
34.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.48
Open$13.14
Day$13.03–13.98
52W close$10.06–16.52
Avg vol 30d144K
Short int2.1M · 6.2% float · 26.7d
Short vol56%
Last earningsMay 14, 2026
DataJul 2023–Aug 2026
Filing10-Q · May 14
Raw chart and full-history price indicators begin at the captured split on Jul 26, 2023; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
+7%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
53%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+24%
trailing
YTD return
0%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.25% of float · ▼ -5.4% MoM · 26.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
86 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−42%
Y/Y
EPS growth
+14%
Y/Y
Free cash flow
$-23.6M
Balance sheet
$97.7M
net cash
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
53%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $12 — 50d above 200d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.25% of float · ▼ -5.4% MoM · 26.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
86 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10
Now $13 · 53%
Range high $17
vs 200-day avg +11%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNTC
this stock
Benitec Biopharma Inc.
|
$463.10M | +0.1% | -42.2% | — | 6.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jul 26, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNTC | +7.3% | +17.5% | +24.5% | +15.1% | +0.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +8.7% | +13.9% | +12.9% | +12.6% | -12.2% |
Key facts
CIK
1808898
CUSIP
08205P209
13F (30d)
80 filings
80 filers
Visit website
Investor relations